在接受68Ga-FAPI-RGD和18F-FDG双示踪剂 PET/CT的患者中,选取17例初始分期的患者进行数据分析,结果显示,68Ga-FAPI-RGD PET/CT在所有原发性肿瘤中检测结果为19/19,而后者漏检3例肿瘤病变和1例多灶性乳腺癌,并且在所有的原发肿瘤中,68Ga-FAPI-RGD PET/CT组的SUVmax值显著高于18F-FDG PET/CT。(中位SUVmax...
因此,患者被诊断为放射性碘难治性分化型甲状腺癌。与 18F-FDG PET/CT 相比,68Ga-FAPI-RGD PET/CT 显示更高的示踪剂摄取和更清晰的病变边界。这表明 177Lu-FAPI-RGD 可能作为放射性碘难治性分化型甲状腺癌的治疗选择。 "点击查看英文标题和摘要"
Results: 68Ga-FAPI-RGD was well tolerated, with no adverse events reported in correlation with the study in any of the patient. The SUVmax and SUVmean of tumor lesions increased, and those of nomal organs decreased over time as shown in dynamic acquisition. Around 2 hours p.i. appeared ...
In gastric cancer, esophagus cancer, breast cancer, intestinal cancer, gliomas, and pancreatic cancer, the quantitative tumor uptake of [68Ga]Ga-FAPI-RGD was noninferior to that of 2-[18F]FDG. For metastatic tumors, [68Ga]Ga-FAPI-RGD PET/CT revealed more PET-positive lesions and higher ...
FAPI-RGDDue to the heterogeneity of tumors, strategies to improve the effectiveness of dual-targeting tracers in tumor diagnostics have been intensively practiced. In this study, the radiolabeled [18F]AlF-NOTA-FAPI-RGD (denoted as [18F]AlF-LNC1007), a dual-targeting heterodimer tracer targeting ...